Company​

  • A Fuji Chemical Holdings company​
  • Established in October 2015​
  • Strong management team with over 40 years of pharma expertise in R&D and Commercialization​

Technology​

  • Synthetic water-soluble analogues of Astaxanthin (small molecule NCEs) ​a naturally occurring substance with anti-inflammatory properties for sustained inflammatory conditions​.
  • Newly identified MOA with this class of compounds – Additional evidence as a mitochondrial nutrient​
  • Proof of Concept in animal models (rodents, rabbits) with the lead compounds​

Focus​

  • Osteoarthritis​
  • ALS​
  • Cerebral infarction​
  • CHF​